This study is looking at a new medicine called PF-07248144. It will be given along with fulvestrant to help people with HR-positive, HER2-negative advanced or metastatic breast cancer. The main goal is to see how safe and effective this combination is for patients whose cancer has progressed after previous treatment.
This is a Phase 3 trial, which means it is looking at how well the treatment works and how safe it is. The trial hopes to include around 400 participants and is FDA-regulated.
Who can join
Participants must be at least 18 years old and can be men or women. They should have HR-positive, HER2-negative breast cancer that is advanced or metastatic. They must have received prior treatment with CDK4/6 inhibitors and have measurable disease. Some medical conditions may prevent participation, but the trial team will confirm eligibility.
Condition
Breast Cancer
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly placed into two groups. One group will receive PF-07248144 with fulvestrant. The other group will receive everolimus with an endocrine therapy of either exemestane or fulvestrant. Treatments will be given over a 28-day cycle, with some medicines taken at home and others given by injection at the clinic.
Where
This trial is enrolling at 102 locations. Recruiting sites are listed first.
Bon Secours Cancer Institute at Memorial Regional Medical Center
Director of the Breast Cancer Center at NYU Langone’s Perlmutter Cancer Center. Treats breast cancer. The main cancer doctor for adults. Manages your treatment and your care team. Recognized at state, national or international level.
Inaugural Jeffrey F. Moley Professor of Endocrine and Oncologic Surgery, WashU. Treats breast cancer. A surgeon is the doctor who removes cancer with an operation (adults). Recognized at state, national or international level.
Microsurgical breast reconstruction specialist, MSK. Treats breast cancer and mouth cancer. Offers microsurgical breast reconstruction, head and neck reconstruction and abdominal wall reconstruction.